Samsung Bioepis and Organon released results from an interchangeability study of its adalimumab biosimilar; Express Scripts announced that it will add Cyltezo as well as 2 other adalimumab biosimilars to its formulary list; Anser Therapeutics will offer therapeutic drug monitoring (TDM) for Idacio.
Samsung Bioepis and Organon released results from an interchangeability study of its adalimumab biosimilar; Express Scripts announced that it will add Cyltezo as well as 2 other adalimumab biosimilars to its formulary list; Anser Therapeutics will offer therapeutic drug monitoring (TDM) for Idacio.
Phase 4 Interchangeability Study
Samsung Bioepis and partner Organon released results from a phase 4, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study evaluating the interchangeability of SB5 (Hadlima), an adalimumab biosimilar, and Humira (reference adalimumab).
The study, conducted from August 2022 to May 2023, included 371 adalimumab-naïve patients with moderate to severe plaque psoriasis recruited from 33 sites in 4 countries (Bulgaria, Czechia, Lithuania, Poland). Patients were treated with the reference product for the first 13 weeks of the study. At week 13, patients who achieved at least a 50% reduction in Psoriasis Area and Severity Index were randomized 1:1 to continue with Humira or switch to SB5.
The study achieved all primary end points (pharmacokinetic end points of area under the plasma concentration-time curve for a dosing interval and peak concentration at week 23-25). Safety, efficacy, and immunogenicity profiles were also similar between treatment arms.
Express Scripts to Cover Cyltezo
After announcing that it would add multiple adalimumab biosimilars to its formulary list, Express Scripts confirmed that one of the products would be Boehringer Ingelheim’s Cyltezo, the only interchangeable adalimumab biosimilar in the United States.
The pharmacy benefit manager shared that Sandoz’ branded and unbranded adalimumab biosimilars (Hyrimoz, adalimumab-adaz) would also be added to the list. Cyltezo is a low-concentration adalimumab biosimilar and only the high-concentration versions of Hyrimoz and unbranded adalimumab-adaz were listed. All 3 biosimilar products will be covered at parity with Humira, and join Amgevita (low-concentration), the first adalimumab biosimilar to launch in the United States, on the list.
“In any industry, competition often leads to lower prices, and until recently, Humira had little competition…. Embracing biosimilars as they come to market builds on our efforts over the past decade to support greater adoption.… We believe that, like generic medications, biosimilars can drive greater affordability for individuals with chronic and complex conditions who need it most," said Adam Kautzner, PharmD, president of Express Scripts.
Evernorth, the parent company of Express Scripts, estimated that biosimilars could save the United States between $225 billion and $375 billion in total pharmacy spend over the next 10 years.
TDM Services for Idacio
Prometheus Laboratories announced that it was collaborating with Fresenius Kabi to support the validation of and access to Anser Therapeutics TDM services for patients receiving Idacio, Fresenius Kabi’s adalimumab biosimilar.
“For many health care professionals, therapeutic drug monitoring has become standard of care when treating inflammatory bowel disease patients with biologics and biosimilars. The availability of Anser testing for new agents, like these biosimilars, supports our mission as clinicians to get our patients expediently and cost-effectively into lasting remission,” said Adam Cheifetz, MD, director, Center for Inflammatory Bowel Diseases at Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical Center.
Anser testing is used by rheumatologists and gastroenterologists to gain objective information that will help inform therapeutic decisions. The collaboration will also be used for patients receiving Fresenius Kabi’s tocilizumab and ustekinumab biosimilars upon market availability.
TDM is testing that measures the amount a certain medication in the blood to make sure the amount of medicine is safe and effective. TDM can help providers determine the best dosages for people taking hard-to-dose medicines, such as biologics for autoimmune diseases, heart drugs, and antibiotics.
“There is evidence on the clinical and health economic value of therapeutic drug monitoring for biologics and biosimilars in autoimmune diseases. The availability of Anser testing for an adalimumab biosimilar like Idacio will be a welcome addition to the care protocol of our Rheumatoid Arthritis patients,” commented Alan J. Kivitz, MD, certified physician investigator, founder, and medical director of the Altoona Center for Clinical Research and Altoona Arthritis and Osteoporosis Center.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.